A single tube of blood can carry molecular clues from an organ the needle never touches, opening a new window into neurological disease. When nerve cells are injured, fragments of their internal machinery can reach the circulation, where sensitive assays can detect them. For patients, the appeal is immediate: A blood draw is familiar, quick, and easy to repeat, making it well suited to diseases that unfold over years and to trials that need to follow change over time. Yet the journey from the brain to the bloodstream can blur a molecule's biological context. A result may indicate injury without showing where it began, what caused it, or whether treatment is correcting the disease process. To recover that context, researchers often turn to cerebrospinal fluid (CSF), which circulates around the brain and spinal cord. The challenge is not to decide whether blood or CSF is superior, but to connect the distinct stories told by both.
Blood Biomarkers Can Signal Brain Injury, but Not Always Its Source
Neurofilament light chain (NfL) captures both sides of this biomarker dilemma. Part of the structural scaffolding that supports nerve fibers, NfL is released into the CSF when nerve fibers are damaged and can also be detected in the bloodstream. This trajectory makes it an accessible marker of neuronal injury, but one that behaves more like a general alarm than a specific address. In a multicenter study of 2,269 participants, plasma NfL was elevated across several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and atypical parkinsonian disorders.1 The result carried an important message that nerve fibers were being injured, but it could not identify the disorder responsible.
A blood measurement may also struggle to distinguish damage in the brain or spinal cord from injury to peripheral nerves, leaving clinicians with evidence of distress but not necessarily its source. The bloodstream adds uncertainty because molecules from the liver, muscles, immune system, and blood vessels vastly outnumber those arriving from the brain. Brain-derived signals may be diluted, cleared, or altered as they cross biological barriers. In a 2025 analysis of CSF and plasma collected from the same 2,171 people, researchers found that the relationship between levels of the same proteins in the two fluids varied with age, cognitive impairment, genetics, and transport across the brain’s barrier systems.2 Blood can clearly carry news from the brain but understanding that news may require a sample collected closer to its source.
Capturing Biological Signals Closer to the Source
The closer sample is CSF, a clear fluid that moves through the brain's ventricles and around the brain and spinal cord. It cushions the central nervous system (CNS), carries signaling molecules, and helps remove waste. Because CSF directly interfaces with CNS tissues, disease-related proteins and peptides may be easier to detect there or appear against a quieter molecular background than in blood. This proximity changes the question from whether nerve cells are under stress to which biological processes are changing. Researchers can look for patterns linked to inflammation, neuronal communication, barrier function, or abnormal RNA processing. CSF is not brain tissue in liquid form. Its composition is influenced by multiple sources, wherein some proteins come from blood and barrier systems regulate what enters and leaves it. Nevertheless, CSF offers one of the closest available views of CNS biology without sampling brain tissue.
The scientific advantage of CSF is inseparable from the difficulty of obtaining it. A lumbar puncture passes a thin needle between bones in the lower back, below the usual end of the spinal cord, to reach the fluid-filled space. Many patients understandably worry about post puncture headache, a concern that calls for clear information rather than reassurance alone. Technique can change the experience: A review of 110 randomized trials involving 31,412 participants found that atraumatic needles reduced post puncture headache from 11.0 percent to 4.2 percent without lowering the procedure's success rate.3 Neurological consensus guidelines similarly recommend small atraumatic needles, screening for contraindications, limiting repeated attempts, and explaining the procedure beforehand.4 These measures do not remove the burden, but they help patients weigh it against the value of the information.
Bridging CSF Discovery and Blood-Based Monitoring
That balance points to a focused role for CSF. Rather than collecting it at every visit, researchers can use it as a discovery bridge: identify a signal near the CNS, determine what it represents, and test whether the same molecule or a dependable companion marker can be measured in blood. Paired samples sharpen each step as a disease-linked molecule that changes in CSF after treatment may help show that the therapy engages its CNS target; one that changes in both fluids and follows the same course may become a candidate for blood monitoring. When a change appears only in blood, the CSF comparison can reveal whether another organ is driving it. The samples therefore act as different, complementary views of the same disease, not competing tests.
Multiomic technologies can bring those views together as proteomics measures protein patterns, genomics and transcriptomics reveal inherited changes and errors in how cells assemble RNA messages, and proteogenomic traces those errors into the protein fragments they may produce. Together, these approaches can connect injury with its likely tissue source, biological pathway, and response to treatment. For instance, a smaller clinical cohort might provide CSF for mechanistic discovery, while blood from a larger cohort provides the scale needed for repeated monitoring. This division of labor matters most when a disease affects several organs and a blood signal may have several possible origins. Myotonic dystrophy type 1 (DM1), for example, is an inherited multisystem disorder best known for progressive muscle weakness, although it also affects the heart, lungs, endocrine system, and central nervous system. That complexity can make the source of a blood biomarker difficult to assign and help explain why DM1 may benefit from viewing disease biology through both CSF and blood.
Why Blood and CSF Tell Different Parts of the DM1 Story
DM1 begins with an expanded CTG repeat in the 3' untranslated region of the dystrophia myotonica protein kinase gene. The expanded RNA gathers in cell nuclei and traps muscleblind-like splicing factors, causing cells to assemble many RNA messages incorrectly. For people living with DM1 and their families, CNS involvement is not an abstract finding. Excessive daytime sleepiness, fatigue, slowed thinking, difficulty planning and organizing, and changes in motivation or behavior can shape education, employment, relationships, and independence. Muscle strength tests do not capture these experiences, while a general blood marker cannot, by itself, explain their underlying biology. A useful biomarker must connect the neurological effects of DM1 to its RNA-splicing defect.
Blood NfL provides part of that picture. In a longitudinal study, levels were higher in 53 people with DM1 than in 70 healthy control samples and were associated with white matter changes on brain scans; participants who had not yet developed clear symptoms had intermediate levels. However, the injury markers changed little across three annual visits.5 The study supports neurological injury, but NfL cannot show whether abnormal RNA splicing is active in the CNS or corrected by therapy. Because DM1 also affects muscle and may involve peripheral nerves, CSF can help establish whether a candidate signal truly reflects the CNS.
Following DM1's Molecular Trail from CNS Symptoms to RNA Splicing
The search for a disease-specific CNS signal begins at the cellular interfaces that shape CSF. The choroid plexus, a network of specialized tissue within the brain’s ventricles that produces much of the CSF and helps regulate its exchange with blood, also appears to participate in DM1-related molecular changes. A study of the choroid plexus identified abnormal RNA splicing in human DM1 tissue and experimental models, with predicted effects on ion balance, secreted proteins, and CSF composition; related alterations also appeared in CSF from people with DM1.6 Those findings suggested that CSF might carry more than a general stress signal. Our 2025 exploratory Stanford study profiled 1,072 CSF proteins from 11 participants with DM1 and five controls, uncovering candidate changes in neural cell adhesion, immune regulation, CSF homeostasis, growth-factor signaling, motor control, and cellular structure.7 The candidates require confirmation in larger, independent, and longitudinal studies, but the pattern begins to connect CNS involvement with particular processes rather than injury alone.
Proteogenomics could follow the trail further as RNA data from affected brain regions can predict unusual protein fragments created by incorrect splicing, and mass spectrometry can search CSF for peptides crossing those altered junctions. This strategy has detected disease-linked peptides generated when TAR DNA-binding protein 43 (TDP-43)-dependent splicing control is lost in ALS and frontotemporal dementia.8 In DM1, a splice-junction peptide could show that the defining error is present in the CNS and whether a splicing-directed therapy is changing it. Once established in CSF, that signal could be tested for blood-based monitoring.
From CNS Mechanism to Blood-Based Monitoring
This translational path from a general blood alarm to CSF biological context, and back to a more informative blood test gives each fluid a role suited to its strengths. CSF can identify CNS-linked proteins, clarify broad injury signals, and help show whether treatment engages its intended pathway; blood can extend those discoveries into larger trials, frequent follow-up, and wider access. The strategy also respects patient burden. It avoids repeated lumbar punctures when a validated blood measurement can answer the question, without treating convenience as proof of brain specificity. When CSF is necessary, modern technique, transparent discussion of risks and benefits, and genuine informed choice should guide its collection.
What Can a Blood Draw Tell Researchers About What is Occurring in the Brain?
It can tell a vital part of the story, but the narrative remains incomplete until researchers understand where the signal originated and which disease process produced it. For DM1 and other disorders targeted by molecular therapies, the goal is to let CSF reveal the mechanism and then use blood to bring that knowledge to more patients.
- Ashton NJ, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.
- Farinas A, et al. Disruption of the cerebrospinal fluid-plasma protein balance in cognitive impairment and aging. Nat Med. 2025;31:2578-2589.
- Nath S, et al. Atraumatic versus conventional lumbar puncture needles: A systematic review and meta-analysis. Lancet. 2018;391(10126):1197-1204.
- Engelborghs S, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement (Amst). 2017;8:111-126.
- van der Plas E, et al. Blood-based markers of neuronal injury in adult-onset myotonic dystrophy type 1. Front Neurol. 2022; 12:791065.
- Nutter CA, et al. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1. Brain. 2023;146(10):4217-4232.
- Zafarullah M, et al. Cerebrospinal fluid proteomic profiling reveals potential biomarkers and altered pathways in myotonic dystrophy type 1. Front Neurosci. 2025;19:1709678.
- Seddighi S, et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. Sci Transl Med. 2024;16(734): eadg7162.


















